Over half of patients in a randomized trial switch from enzalutamide to darolutamide because of cognitive issues; no one switches in the opposite direction.

Participants on weekly injections of 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks, and 45.3% of participants achieved ≥ 30% weight loss.

Analysis of data from the PUSH randomized trial affirmed that more fluid increase is better, but some still helps.

A new study finds that prior authorization requirements vary widely across major insurers and suggests large language models ...

Biopsy and next-generation sequencing identified an HSV 1 variant causing ulcerative esophagitis and ileitis in a healthy 26 ...

Pediatric hypertension is a significant concern because it can persist into adulthood and contribute to cardiovascular ...

Creatinine muscle index can serve as a blood biomarker to estimate low muscle mass and identify individuals at an increased ...

An analysis conducted in an integrated healthcare system provided insights into the long-term healthcare burden of cCMV ...

Rapid microbiological point-of-care testing for respiratory tract infections does not reduce overall same-day antibiotic prescribing in primary care, a recent study shows.

Health leaders in Spain debate balancing maternal-fetal safety with respectful, informed care, spotlighting birth plans, ...

One fifth of pregnant women are not being screened in a timely manner for syphilis, according to a new study in Ontario.

The FDA’s recent approval of baxdrostat may usher in new possibilities for treatment for uncontrolled hypertension.